Xeris (XERS) Q2 2026 Earnings Call Transcript
Xeris (XERS) Q2 2026 earnings call said it retired its convertible notes, eliminating nearly $3 million in annual interest expense. The company raised full-year 2026 total revenue guidance to $385 million to $390 million. Q2 net product revenue was $91 million (+34% YoY) and total revenue $92.1 million (+29%). Recorlev net revenue was $56.8 million (+81% YoY), Gvoke about $23 million, and Keveyis nearly $12 million. It also reported new U.S. patent allowances for Keveyis and XP-8121.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised 2026 revenue guidance range, the reported Q2 revenue growth and brand net revenue figures, and the July convertible note retirement that reduces annual interest expense.
Market read
Traders can update 2026 revenue expectations and capital-structure risk after the guidance raise and convertible note retirement, while monitoring XP-8121 Phase III execution into September’s webinar.
What to watch
The transcript emphasizes IP allowances and planned Phase III start by year end, but does not provide Phase III design details or funding needs, which could matter for valuation and risk pricing.
Background
Xeris’ Q2 2026 earnings call highlights commercial momentum across Recorlev, Gvoke, and Keveyis, plus pipeline progress for XP-8121 and a simplified capital structure after retiring convertible notes.
Ticker impact
Xeris raised the bottom end of 2026 total revenue guidance to $385M to $390M and reported Q2 revenue growth and brand updates.
Moderately positive bias for the next few sessions as traders reprice 2026 revenue expectations and de-risk the capital structure.
The transcript includes specific, decision-relevant numbers (guidance range, Q2 revenue and brand net revenue) and a concrete financing event (convertible notes fully retired in July).
Market effects
Reinforces demand and commercial execution in rare-disease endocrinology and may support sentiment toward profitable biopharma with durable branded revenue.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, as the disclosures are company-specific and US-focused (US patents, US revenue guidance).
Counterpoint
Raised guidance could still be conservative if XP-8121 Phase III timing or enrollment costs slip, offsetting near-term brand strength.
Key entities
- companyXeris
Biopharmaceutical company reporting Q2 2026 results, raising 2026 revenue guidance, and detailing brand and pipeline progress.
- productRecorlev
Endogenous Cushing’s syndrome therapy with Q2 net revenue near $57M and 81% YoY growth.
- productGvoke
Glucagon hypo-pen therapy with Q2 net revenue around $23M and sequential improvement.
- productKeveyis
Ultra-rare PPP community therapy with nearly $12M net revenue and a new US patent allowance for extended protection.
- pipeline_programXP-8121
Hypothyroidism program with additional US patent activity and planned Phase III start by year end.
